Answers are grounded in this paper and cite their sources.
Abstract ID 130932 Poster Board 043 Benzalkonium chlorides (BACs) are quaternary ammonium antimicrobials widely applied in domestic, agricultural, clinical, and industrial settings (e.g., disinfectant sprays, food processing, pharmaceutical formulations, wood preservation, etc.). Despite the widespread usage of BACs for over 70 years, the FDA is now seeking additional safety data on their usage in healthcare and consumer antiseptic products, including information on pharmacokinetics, ADME, and BAC metabolites. Literature suggests BACs are absorbed following oral ingestion, and biomonitoring studies have found that BACs are detectable in up to 98% of human blood samples; However, there is little information available on the presence or levels of BAC metabolites. The study presented here describes the disposition of BACs, including metabolites, in C57BL/6 male and female mice following oral exposure to C12-BAC or C16-BAC at 120 μg /g/day for one week. UPLC-MS/MS analysis of tissue extracts (brain, heart, spleen, lung, liver, kidney, intestine), as well as fecal, urine, and blood samples from BAC-treated mice demonstrated the absorption and metabolism of BACs. Both parent compounds, C12- and C16-BAC, were detected in all the aforementioned tissues with levels from highest to lowest in the following order (big intestine (1.4-18 μM), ileum (0.6-5 μM), jejunum (3.2-13 μM), duodenum (1-8μM), spleen (15-72 nM), heart (10-370nM), liver (11-60 nM), lung (3-274 nM), brain (149-1550 pM)), whereas BAC metabolites were detected in all tissues except for brain or spleen. Our lab previously discovered that BAC metabolism is mediated by cytochrome P450 (CYP) enzymes, with ω- and ω-1 oxidized BACs (hydroxy, ketone, diol, and COOH) presenting as the major products of human BAC metabolism. Similar to the human metabolism, major metabolites quantified in mice were the ω- and (ω-1)-oxidized metabolites, as well as β-oxidized BAC-COOH products. Notably, metabolite to parent ratios within the aforementioned tissues highlight metabolizing capability in liver, intestine, lung and heart. Of all analytes quantified within the liver, up to 90% of them are metabolites. Furthermore, evidence of metabolizing capability in other tissues like lung (up to 70%), heart (50%), and intestine (80%) demonstrate novel understandings of BAC disposition and metabolism within an in-vivo model. Additionally, our work demonstrates evidence of preferential metabolism of C16-BAC over C12-BAC. Within big intestine, and fecal extracts at two separate time points (day 4 and day 7), there are higher metabolite to parent ratios in the C16-BAC treated mice (80%) compared to the C12-BAC treated mice (50%). Previous work in human microsomes has evaluated the metabolizing capability of the following tissues in the order of liver, kidney, intestine and lung. Future studies will assess the metabolic capacities of specific tissues by measuring rates of BAC metabolism in liver, lung, and kidney microsomes prepared from both male and female BAC-treated and untreated mice. Together, this work advances our understanding of BAC biodistribution and metabolism.
No takes yet. Share an insight, caveat, or question.
López‐Ozuna et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: